Clinical Trials
33 trialsBiomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
Seoul National University Hospital
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
Seoul National University Hospital
NEO
University Health Network, Toronto
Olaparib Maintenance Therapy in Metastatic Breast Cancer
National Taiwan University Hospital
OPTI-DOSE
University Medical Center Groningen
Olaparib and Radiotherapy in Head and Neck Cancer
The Netherlands Cancer Institute
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
Fudan University
WIRE
Cambridge University Hospitals NHS Foundation Trust
MITO 31
National Cancer Institute, Naples
PEMBROLA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
California Pacific Medical Center Research Institute
The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
ICON9
University College, London
BOLD
ARCAGY/ GINECO GROUP
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
Saitama Medical University International Medical Center
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
COPELIA
University of Manchester
PROspect
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Massachusetts General Hospital
DOMEC
Leiden University Medical Center
CLIO
Universitaire Ziekenhuizen KU Leuven
ANLOLA
Jiangsu Cancer Institute & Hospital
NUVOLA
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
TOPARP
Institute of Cancer Research, United Kingdom
SOLAR
Royal Marsden NHS Foundation Trust
plasmaMATCH
Institute of Cancer Research, United Kingdom
PIN
Velindre NHS Trust
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Swedish Medical Center
Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
Poveda, Andrés, M.D.
Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients
Istituti Ospitalieri di Cremona
ROCOCO
The Christie NHS Foundation Trust